Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward [0.03%]
印度卫生技术评估的现状及未来展望：政策制定方面的应用
Shankar Prinja,Laura E Downey,Vijay K Gauba et al.
Shankar Prinja et al.
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada [0.03%]
贝伐单抗治疗加拿大铂耐药复发性卵巢癌的经济评估
Graeme Ball,Feng Xie,Jean-Eric Tarride
Graeme Ball
Background: Ovarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden. ...
Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review [0.03%]
离散选择试验方法在烟草控制领域中的应用：系统综述
Kabindra Regmi,Dinesh Kaphle,Sabina Timilsina et al.
Kabindra Regmi et al.
Background: Economic evidence relating to tobacco control is generally derived from the cost effectiveness of smoking-cessation programs or the economic impact of tobacco-induced disease, based on revealed-preference data...
Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease [0.03%]
哪些成本重要？稳定型冠心病经济评价中纳入的成本及其对决策不确定性的的影响
James Lomas,Miqdad Asaria,Laura Bojke et al.
James Lomas et al.
Background: Variation exists in the resource categories included in economic evaluations, and National Institute for Health and Care Excellence (NICE) guidance suggests the inclusion only of costs related to the index con...
Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations [0.03%]
缺失数据在成本效用分析中的处理方法：综述及未来研究方向
Andrea Gabrio,Alexina J Mason,Gianluca Baio
Andrea Gabrio
Published Erratum
PharmacoEconomics - open. 2017 Jun;1(2):143. DOI:10.1007/s41669-017-0029-0 2017
Christopher James Sampson,Tim Wrightson
Christopher James Sampson
Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations [0.03%]
处理试验内成本效益分析中的缺失数据：回顾与未来建议
Andrea Gabrio,Alexina J Mason,Gianluca Baio
Andrea Gabrio
Cost-effectiveness analyses (CEAs) alongside randomised controlled trials (RCTs) are increasingly designed to collect resource use and preference-based health status data for the purpose of healthcare technology assessment. However, because...
Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes [0.03%]
一次性柔性支气管镜可能的成本效益的早期评估
Christoffer Lilja Terjesen,Julia Kovaleva,Lars Ehlers
Christoffer Lilja Terjesen
Background: Bronchoscopic procedures are common in the clinical setting, with estimates indicating 500,000 are undertaken per year in the USA alone. These procedures are generally regarded as safe. Unfortunately, a risk o...
Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years' Experience 1991-2015 [0.03%]
美国梅迪卡项目中喹诺酮类药物的利用、花费与价格变化：1991-2015年25年的经验总结
Ziyad S Almalki,Xiaomeng Yue,Ying Xia et al.
Ziyad S Almalki et al.
Background: Given that the quinolones is one of the antibacterial classes most frequently used to treat patients with bacterial infections in the United States, any change in prescribing patterns of quinolones will impact...
Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas [0.03%]
希腊偏远地区的远程医疗系统/单位的成本效益分析
Marios-Nikolaos Kouskoukis,Charalambos Botsaris
Marios-Nikolaos Kouskoukis
Background: Telemedicine units and information technology systems provide special healthcare services to remote populations using telecommunication technology, in order to reduce or even remove the usual and typical face-...